

Form 51-102F3
Material Change Report Under
National Instrument 51-102

1. Name and Address of Reporting Issuer

Sona Nanotech Inc.
1969 Upper Water Street, Suite 2001
Purdy's Wharf Tower II
Halifax, NS B3J 3R7

2. Date of Material Change

Effective November 2, 2020.

3. News Release

A news release with respect to the material change referred to in this report was issued on November 3, 2020 and filed on the system for electronic document analysis and retrieval (SEDAR).

4. Summary of Material Change

Sona Nanotech Inc. (CSE: SONA) (the "Company") has announced that Mr. Mark Lievonen has been elected as a Director of the Company following the resignation of Mr. Zephaniah Mbugua effective November 2, 2020.

The Company also announced the issuance of 250,000 stock options to Mr. Lievonen.

5. Full Description of Material Change

The Company announced the appointment of Mr. Mark Lievonen to the Company's Board of Directors on November 2, 2020. Mr. Lievonen is the former President of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi. Under his leadership, Sanofi Pasteur became a billion dollar enterprise in Canada, manufacturing over 50 million doses of vaccines for both domestic and international markets. Mr. Lievonen spearheaded a cancer vaccine program and supported the launch of a five-component pertussis vaccine, which is widely used to this day. He has also served on a number of public and not-for-profit boards and industry organizations including as Chair of BIOTECanada and Rx&D (now Innovative Medicines Canada).

Currently, Mr. Lievonen is the Co-Chair of the Government of Canada's COVID-19 Vaccine Task Force, a Director of OncoQuest Pharmaceuticals Inc., Biome Grow Inc., and the Gairdner Foundation. He holds a BBA in accounting and a MBA in finance and marketing from the Schulich School of Business, York University, and is a FCPA.

Mr. Lievonen is replacing Mr. Zephaniah Mbugua, who has served on the Company's Board since August 2018.

The Company has also issued 250,000 stock options to Mr. Lievonen. Each option is exercisable at \$3.36 and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Stock Option Plan.

6. Reliance on Subsection 7.1(2) of National Instrument 51-102

Not applicable.

7. Omitted Information

Not applicable.

8. Senior Officer

The following officer of the Sona Nanotech may be contacted for further information:

| | |
|-------------|-------------------------|
| David Regan | Chief Executive Officer |
| Telephone: | (902) 536-1932 |
| Email: | david@sonanano.com |

DATED at Halifax, Nova Scotia this 12th day of November, 2020.

Sona Nanotech Inc.

By: (s) David Regan
David Regan,
Chief Executive Officer